Browse > Article
http://dx.doi.org/10.3961/jpmph.2012.45.4.219

Zolpidem Use and Risk of Fracture in Elderly Insomnia Patients  

Kang, Dong-Yoon (Department of Preventive Medicine, Seoul National University College of Medicine)
Park, So-Young (Department of Preventive Medicine, Seoul National University College of Medicine)
Rhee, Chul-Woo (Department of Preventive Medicine, Seoul National University College of Medicine)
Kim, Ye-Jee (Department of Preventive Medicine, Seoul National University College of Medicine)
Choi, Nam-Kyong (Medical Research Collaborating Center, Seoul National University Hospital)
Lee, Joong-Yub (Medical Research Collaborating Center, Seoul National University Hospital)
Park, Byung-Joo (Department of Preventive Medicine, Seoul National University College of Medicine)
Publication Information
Journal of Preventive Medicine and Public Health / v.45, no.4, 2012 , pp. 219-226 More about this Journal
Abstract
Objectives: To evaluate the risk of fractures related with zolpidem in elderly insomnia patients. Methods: Health claims data on the entire South Korean elderly population from January 2005 to June 2006 were extracted from the Health Insurance Review and Assessment Service database. We applied a case-crossover design. Cases were defined as insomnia patients who had a fracture diagnosis. We set the hazard period of 1 day length prior to the fracture date and four control periods of the same length at 5, 10, 15, and 20 weeks prior to the fracture date. Time independent confounding factors such as age, gender, lifestyle, cognitive function level, mobility, socioeconomic status, residential environment, and comorbidity could be controlled using the case-crossover design. Time dependent confounding factors, especially co-medication of patients during the study period, were adjusted by conditional logistic regression analysis. The odds ratios and their 95% confidence intervals (CIs) were estimated for the risk of fracture related to zolpidem. Results: One thousand five hundred and eight cases of fracture were detected in insomnia patients during the study period. In our data, the use of zolpidem increased the risk of fracture significantly (adjusted odds ratio [aOR], 1.72; 95% CI, 1.37 to 2.16). However, the association between benzodiazepine hypnotics and the risk of fracture was not statistically significant (aOR, 1.00; 95% CI, 0.83 to 1.21). Likewise, the results were not statistically significant in stratified analysis with each benzodiazepine generic subgroup. Conclusions: Zolpidem could increase the risk of fracture in elderly insomnia patients. Therefore zolpidem should be prescribed carefully and the elderly should be provided with sufficient patient education.
Keywords
Zolpidem; Bone fractures; Case-crossover design; Aged; Hypnotic; Sleep initiation and maintenance disorders;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ohayon MM, Hong SC. Prevalence of insomnia and associated factors in South Korea. J Psychosom Res 2002;53(1):593-600.
2 Cho YW, Shin WC, Yun CH, Hong SB, Kim J, Earley CJ. Epidemiology of insomnia in Korean adults: prevalence and associated factors. J Clin Neurol 2009;5(1):20-23.
3 Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004;164(17):1888-1896.
4 Korean NeuroPsychiatric Association. Textbook of neuropsychiatry. 2nd ed. Seoul: Jungangmunhwa Co.; 2005, p. 670-682 (Korean).
5 Stone KL, Ensrud KE, Ancoli-Israel S. Sleep, insomnia and falls in elderly patients. Sleep Med 2008;9(Suppl 1):S18-S22.
6 Maczaj M. Pharmacological treatment of insomnia. Drugs 1993; 45(1):44-55.
7 Richey SM, Krystal AD. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011;17(15):1471-1475.
8 Lenhart SE, Buysse DJ. Treatment of insomnia in hospitalized patients. Ann Pharmacother 2001;35(11):1449-1457.
9 Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Morland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008;9(8):818-822.
10 King MB. Is there still a role for benzodiazepines in general practice? Br J Gen Pract 1992;42(358):202-205.
11 Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40(2):291-313.
12 Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12(11):814-828.
13 Bogan RK. Treatment options for insomnia: pharmacodynamics of zolpidem extended-release to benefit next-day performance. Postgrad Med 2008;120(3):161-171.
14 Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998;13(4):157-167.
15 Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995;18(4):246-251.
16 Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992;20(2):162-
17 Allain H, Monti J. General safety profile of zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 1997; 12(Suppl 1):21-29.
18 Lee YJ. Overview of the therapeutic management of insomnia with zolpidem. CNS Drugs 2004;18(Suppl 1):17-23.
19 Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18(5):297-328.
20 Mendelson WB. Sleepwalking associated with zolpidem. J Clin Psychopharmacol 1994;14(2):150.
21 Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. Manifestations and management of chronic insomnia in adults. Evid Rep Technol Assess (Summ) 2005;(125): 1-10.
22 Iruela LM. Zolpidem and sleepwalking. J Clin Psychopharmacol 1995;15(3):223.
23 Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009;5(5):471-476.
24 Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem--sleepwalking: a case report. Arch Phys Med Rehabil 2005;86(6):1265-1266.
25 Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010;19(12):1248-1255.
26 Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331(7526):1169.
27 Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001; 49(12):1685-1690.
28 Antai-Otong D. The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults. Perspect Psychiatr Care 2006;42(3):196-200.
29 Ki M. Theory and practice of case-crossover study design. Korean J Epidemiol 2008;30(1):1-11 (Korean).
30 Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133(2):144-153.
31 Frost M, Abrahamsen B, Masud T, Brixen K. Risk factors for fracture in elderly men: a population-based prospective study. Osteoporos Int 2012;23(2):521-531.
32 Maclure M. 'Why me?' versus 'why now?' Differences between operational hypotheses in case-control versus case-crossover studies. Pharmacoepidemiol Drug Saf 2007;16(8):850-853.
33 McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, Mac- Donald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998;7(4):275-280.
34 Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003;348(1):42-49.
35 Hong GR, Cho SH, Tak Y. Falls among Koreans 45 years of age and older: incidence and risk factors. J Adv Nurs 2010;66(9): 2014-2024.
36 Chang CM, Chen MJ, Tsai CY, Ho LH, Hsieh HL, Chau YL, et al. Medical conditions and medications as risk factors of falls in the inpatient older people: a case-control study. Int J Geriatr Psychiatry 2011;26(6):602-607.
37 Vitry AI, Hoile AP, Gilbert AL, Esterman A, Luszcz MA. The risk of falls and fractures associated with persistent use of psychotropic medications in elderly people. Arch Gerontol Geriatr 2010;50(3):e1-e4.
38 Richey SM, Krystal AD. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011;17(15):1471-1475.
39 Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32(6):680-691.
40 Ravera S, van Rein N, de Gier JJ, de Jong-van den Berg LT. Road traffic accidents and psychotropic medication use in The Netherlands: a case-control study. Br J Clin Pharmacol 2011; 72(3):505-513.